–Lauren Ruhland, 2008 MCPP intern
I’m not an expert on health issues, but among the biggest projects of my academic career was a research presentation on advancements in the treatment of cervical cancer, the culmination of countless hours of research during my final semester. In particular, my project focused on new vaccine technologies that promise protection against human papillomavirus (HPV). HPV is a common (and incurable) STD that causes virtually all cancers of the uterine cervix. Gardasil was the first vaccine against the disease approved by the FDA.
As with any new medical technology, there are risks to consider before getting vaccinated (or choosing to vaccinate your child.) If it were up to Erin Brockovich, though, you wouldn’t even have to make that decision. No, she doesn’t want to make HPV vaccines mandatory– though many state legislatures have tried to do effectively that. Instead, Brockovich siezes on reports of a few tragic deaths that have occurred after vaccination and concludes that Gardasil manufacturer Merck is killing young girls in the pursuit of profits.
I’m taking her blog post on point-by-point, here. It’s pretty long, so consider yourself warned.
Gardasil, as you should know by now, is an HPV vaccine sold by Merc(sic), a vaccine with a flawed marketing campaign targeting young girls. The premise is that the vaccine will protect young girls from cervical cancer, as well as a couple of varieties of HPV.
The vaccine prevents infection with four varieties of HPV– two are associated with cervical cancer, while the other two are associated with genital warts, an unpleasant but not deadly disease. Though there are many risk factors for cervical cancer, like tobacco use and family history, these factors are not sufficient on their own to cause the disease. Upwards of 99% of cervical cancers are directly associated with HPV infection, though most women with HPV won’t ever get cancer.
Since young women are the most likely to be infected with HPV and the benefits of vaccination greatest for females, that’s where Merck chose to focus its research. Because the research was conducted among this age group, the FDA has only approved the vaccine for girls and women between the ages of 11 and 27. Continue reading →